These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27892793)

  • 21. Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice.
    Liu S; Humphreys SC; Cook KD; Conner KP; Correia AR; Jacobitz AW; Yang M; Primack R; Soto M; Padaki R; Lubomirski M; Smith R; Mock M; Thomas VA
    MAbs; 2023; 15(1):2263926. PubMed ID: 37824334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice.
    Chen X; Jiang X; Doddareddy R; Geist B; McIntosh T; Jusko WJ; Zhou H; Wang W
    J Pharmacol Exp Ther; 2018 Apr; 365(1):140-155. PubMed ID: 29420255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection.
    Pasquiers B; Benamara S; Felices M; Nguyen L; Declèves X
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.
    Chetty M; Li L; Rose R; Machavaram K; Jamei M; Rostami-Hodjegan A; Gardner I
    Front Immunol; 2014; 5():670. PubMed ID: 25601866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies.
    Elmeliegy M; Lowe P; Krzyzanski W
    AAPS J; 2014 Jul; 16(4):810-42. PubMed ID: 24871341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Balthasar JP; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease.
    Chen X; Farrokhi V; Singh P; Ocana MF; Patel J; Lin LL; Neubert H; Brodfuehrer J
    MAbs; 2018 Jan; 10(1):62-70. PubMed ID: 29190188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.
    Yuan D; Rode F; Cao Y
    Eur J Pharm Sci; 2019 Oct; 138():105032. PubMed ID: 31394258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.
    Singh AP; Krzyzanski W; Martin SW; Weber G; Betts A; Ahmad A; Abraham A; Zutshi A; Lin J; Singh P
    AAPS J; 2015 Mar; 17(2):389-99. PubMed ID: 25445845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target-mediated drug disposition model for drugs that bind to more than one target.
    Gibiansky L; Gibiansky E
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):323-46. PubMed ID: 20669044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).
    Ahlberg J; Giragossian C; Li H; Myzithras M; Raymond E; Caviness G; Grimaldi C; Brown SE; Perez R; Yang D; Kroe-Barrett R; Joseph D; Pamulapati C; Coble K; Ruus P; Woska JR; Ganesan R; Hansel S; Mbow ML
    MAbs; 2019 Jul; 11(5):956-964. PubMed ID: 31068073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.
    Sharma A; Davis CB; Tobia LA; Kwok DC; Tucci MG; Gore ER; Herzyk DJ; Hart TK
    J Pharmacol Exp Ther; 2000 Apr; 293(1):33-41. PubMed ID: 10734150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.
    Kamath AV
    Drug Discov Today Technol; 2016; 21-22():75-83. PubMed ID: 27978991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.
    Mould DR; Green B
    BioDrugs; 2010 Feb; 24(1):23-39. PubMed ID: 20055530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus.
    Wiczling P; Rosenzweig M; Vaickus L; Jusko WJ
    J Clin Pharmacol; 2010 May; 50(5):494-506. PubMed ID: 19934031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and immunogenicity investigation of a human anti-interleukin-17 monoclonal antibody in non-naïve cynomolgus monkeys.
    Han C; Gunn GR; Marini JC; Shankar G; Han Hsu H; Davis HM
    Drug Metab Dispos; 2015 May; 43(5):762-70. PubMed ID: 25739974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.
    Luu KT; Bergqvist S; Chen E; Hu-Lowe D; Kraynov E
    J Pharmacol Exp Ther; 2012 Jun; 341(3):702-8. PubMed ID: 22414855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
    Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
    J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.